Cochrane · systematic review · CD005181
Interferon beta for secondary progressive multiple sclerosis
La Mantia, L, Vacchi, L, Di Pietrantonj, C, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 4 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
INTERFERONS for secondary progressive multiple sclerosis
Population: patients with secondary progressive multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sustained (6 months) EDSS increase after 3 years | RR 0.98 [0.82, 1.16] | 3 studies · 2026 participants | High |
Sustained (3 months) EDSS increase after 3 years | RR 0.88 [0.8, 0.97] | 2 studies · 1336 participants | High |
Sustained (3 or 6 months) EDSS increase at 3 years in patients with pre study relapses | RR 0.9 [0.75, 1.09] | 3 studies · 1106 participants | High |
Number of patients with at least one relapse during | RR 0.91 [0.84, 0.97] | 4 studies · 2639 participants | High |